InvestorsHub Logo
Post# of 252308
Next 10
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

Re: dewophile post# 52090

Monday, 09/10/2007 2:09:20 PM

Monday, September 10, 2007 2:09:20 PM

Post# of 252308
JAV

Another pretty huge advantage is the fact that Dyloject is stable at room temperature and does not require the intermediate step of pharmacy mixing before administration.

Intravenous infusions of Voltarol have to be freshly made up and used immediately. Once prepared, the infusion should not be stored.

In practice, what happens with these kinds of drugs is the pharmacy makes up N bags in the morning based on anticipated usage. Those that are not used are tossed at the end of the day. So you've just wasted the pharmacy time and the drug if it's not used.

Plus would you rather take the very expensive bed time and personnel cost to infuse, or would you rather administer the drug in a quick 30-second bolus?

If you were a hospital administrator, would you rather have a drug that needs to be mixed by the pharmacy and tossed at the end of the day, or would you rather just pop 20 vials of Dyloject in the Pyxis and forget about them until they're needed?

It's pretty clear that Voltarol is a dead duck when Dyloject is approved. It's also clear that a premium can be demanded for this drug--probably even more than they're anticipating.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.